Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBCImprovements […]
NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that […]